Os 100 melhores médicos de quimioterapia para cancro da mama do mundo

O médico é um oncologista altamente respeitado no Centro Médico Anadolu, especializado em oncologia médica e quimioterapia. Após obter um diploma de medicina pela Universidade de Ancara em 2005, o médico completou treinamento especializado em medicina interna na Universidade de Istambul e se especializou ainda mais em oncologia médica na Universidade de Marmara até 2017. O médico liderou a unidade de oncologia médica no Hospital de Treinamento e Pesquisa Haydarpaşa Numune e participou de numerosos estudos clínicos internacionais. O médico foca em uma ampla gama de cânceres, incluindo câncer de mama, urológicos, pulmonares e gastrointestinais, entre outros.<\/p>

O médico é membro de várias sociedades oncológicas de prestígio, incluindo a Sociedade Turca de Oncologia Médica, a Sociedade Europeia de Oncologia Médica e a Sociedade Americana de Oncologia Médica. O médico participou de programas de treinamento avançado globalmente, incluindo programas na Universidade de Oxford e ESMO.<\/p>

O Dr. LV Xiao Jun é um especialista nacional em psico-oncologia. Ele atua como Diretor Executivo de Oncologia Médica no Xiamen Humanity Hospital. O Dr. LV concentra-se no tratamento do câncer de pulmão, mama e gastrointestinal. Ele integra o rastreamento de sofrimento psicológico na terapia tumoral.

• Membro do Comitê Permanente do ramo de psico-oncologia da Associação Chinesa contra o Câncer.
• Especialista em manejo de câncer de pulmão para a Associação contra o Câncer de Fujian.
• Atua em um hospital de nível terciário que trata 1.000.000 de pacientes por ano.
• Trata tumores sólidos usando métodos abrangentes e técnicas de cuidados paliativos.

O Professor Dr. Sezer Saglam é especializado em oncologia médica, com vasta experiência em quimioterapia para câncer de mama no Hospital Gayrettepe Florence Nightingale.

• Formado no Instituto de Oncologia da Universidade de Istambul
• Membro da ESMO, ASCO e da Associação Turca de Oncologia Médica
• Lidera o Departamento de Oncologia Médica no Gayrettepe Florence Nightingale desde 2001

O médico formou-se na Faculdade de Medicina da Universidade de Ancara e completou a residência em medicina interna na Faculdade de Medicina de Ancara GATA. Especializando-se em oncologia médica e hematologia, o médico completou uma bolsa clínica nos EUA. Pioneiro na Turquia, o médico fez parte da equipe que realizou o primeiro transplante de medula óssea no país. O médico atuou como professor visitante em instituições de prestígio em Londres e Suíça. Detentor do Certificado Europeu de Oncologia Médica, o médico é membro fundador tanto da Sociedade Turca de Oncologia Médica quanto do Grupo Oncológico Turco. O foco clínico inclui câncer de mama, gastrointestinal, pulmão, linfomas e mieloma.<\/p>

Especializado em quimioterapia, imunoterapia e terapia direcionada para câncer de mama no Centro Médico em Solingen.

• 14 anos de experiência em hematologia e oncologia
• Médico-chefe de um centro oncológico interdisciplinar certificado
• Especialista em diagnóstico molecular e tratamentos inovadores
• Membro de sociedades oncológicas alemãs e americanas
• Especialista qualificado em genética para terapia personalizada

A Dra. Séverine Iborra lidera a Clínica de Senologia/Mama no Bergisches Breast Center em Solingen, especializando-se no tratamento do cancro da mama.

• Chefe de Ginecologia e Obstetrícia no Städtisches Klinikum Solingen
• Especialista em Oncologia Ginecológica com qualificações adicionais em diagnóstico oncológico
• Membro ativo das principais sociedades médicas alemãs de ginecologia e obstetrícia
• Experiente em tratamentos minimamente invasivos, incluindo laparoscopia e cirurgia robótica
• Autora de numerosas publicações e oradora em importantes conferências ginecológicas

Especialista em ginecologia oncológica e radioterapia – Tamar Sapra concentra-se no tratamento do cancro da mama no Centro Médico Sourasky.

• Experiência tanto em quimioterapia como em radioterapia para cancros ginecológicos
• Dedicada a planos de tratamento personalizados adaptados às necessidades de cada paciente
• Trabalha num dos principais centros médicos de Israel

O Dr. Mutlu é especializado em quimioterapia e terapias direcionadas para o cancro da mama no complexo hospitalar Medical Park Antalya.

• Formado em oncologia médica na Universidade de Akdeniz
• Especialista em investigação genética de nova geração para o tratamento do cancro
• Oferece opções de imunoterapia e medicina complementar
• Professor associado com vasta experiência académica

Diretor de hospitalização oncológica no Centro Médico de Tel Aviv – O Dr. Stepfansky traz uma profunda experiência em quimioterapia para câncer de mama em uma instituição de referência.

• _doctor_3400_anos_ de experiência em oncologia
• Especializado em medicina interna e oncologia
• Pesquisador principal em múltiplos ensaios clínicos
• Formado na Universidade de Grodno e no Centro Médico de Tel Aviv

O Dr. Alemdar especializa-se em oncologia médica com formação extensiva na Universidade de Akdeniz – uma das principais faculdades de medicina da Turquia.

• Certificado em oncologia médica desde 2018
• Mais de _doctor_9570_ anos de experiência em cuidados oncológicos
• Trabalha no complexo hospitalar Medical Park Antalya
• Formado no Hospital Universitário de Akdeniz em oncologia avançada

O Dr. Fredi Aviv traz 34 anos de experiência especializada em onco-hematologia no Sourasky Medical Center (Clínica Ichilov).

• Especializado em quimioterapia para câncer de mama
• Longa prática em um centro médico de referência
• Foca em planos de tratamento personalizados

O Dr. Liu Shi Xin é vice-presidente do Ramo de Oncologia Radioterápica da Associação Médica Chinesa. Ele atua como Líder de Disciplina do Centro de Oncologia no Hospital Xiamen Humanity. O Dr. Liu é especializado em radioterapia de precisão para cânceres torácicos e abdominais. Ele é beneficiário do Subsídio Governamental Especial do Conselho de Estado por suas contribuições médicas.

• Altamente proficiente em IMRT, VMAT e SBRT para cânceres de pulmão e esôfago.
• Ex-presidente do Hospital Oncológico da província de Jilin.
• Premiado com a honra de Médico Nacional Famoso por suas contribuições notáveis à oncologia.
• Ocupa cargos de liderança no comitê de terapia de partículas da Associação Chinesa contra o Câncer.

O Dr. Baha Zengel é especializado em cirurgia oncoplástica da mama e técnicas conservadoras, com mais de duas décadas de experiência no Hospital de Formação e Investigação de Izmir Bozyaka.

• Realiza técnicas avançadas ROLL e SNOLL para a remoção precisa de tumores
• Especialista em mastectomias com conservação de pele e mama com reconstruções
• Doutorado em Oncologia Básica pela Universidade Dokuz Eylül
• Membro da direção da Associação de Oncologia Básica desde 2016

O Prof. Cemil Bilir é especializado em quimioterapia para câncer de mama, com uma sólida formação acadêmica e clínica.

• Oncologista clínico certificado com _doctor_9620_ anos de experiência
• Membro da ASCO e da ESMO – segue padrões globais de tratamento
• Professor na Faculdade de Medicina da Universidade de Sakarya
• Realizou rotações especializadas na Cleveland Clinic

O professor associado Tahsin Ozatli especializa-se em cânceres de mama, pulmão e gastrointestinais no Hospital Universitário Istinye Liv.

• Mais de uma década de experiência em oncologia
• Trabalhou na Clínica de Oncologia de Ancara e no Hospital Regional de Treinamento e Pesquisa de Erzurum
• Promovido a professor associado em 2016
• Graduado pela Faculdade de Medicina da Universidade de Selcuk

O Dr. Ozden especializa-se em oncologia médica, com formação extensiva na Faculdade de Medicina Cerrahpaşa da Universidade de Istambul.

• Concluiu a residência em medicina interna numa instituição de prestígio
• Subespecialização em oncologia médica na Universidade de Kocaeli
• Mais de _doctor_10151_anos_ de experiência em medicina interna e oncologia
• Trabalhou em vários hospitais, incluindo o Hospital Estatal de Şırnak

Professor de Oncologia Médica com mais de _doctor_10980_ anos de experiência, especializado no tratamento do cancro da mama no Hospital Liv da Universidade İstinye em Topkapı.

• Formação especializada em Oncologia Médica na Universidade de Trakya
• Professor associado e posteriormente professor na Faculdade de Medicina da Universidade de Trakya
• Vasta experiência em quimioterapia para cancro da mama
• Membro da comunidade médica turca com uma sólida formação académica

O Professor Associado Muhammed Mustafa Atci é especializado em oncologia médica no Hospital İstinye University Liv Topkapı, com foco no tratamento do câncer de mama.

• Publicou vários estudos sobre os resultados do tratamento do câncer de mama e protocolos terapêuticos
• Membro da Sociedade Americana de Oncologia Clínica (ASCO) e da Sociedade Turca de Oncologia Médica
• Coordenador educacional da subespecialidade de oncologia médica no Hospital Municipal Prof. Dr. Cemil Taşcıoğlu

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

Chefe do Centro de Tratamento de Câncer de Mama com fellowship no Sloan-Kettering – A Dra. Jablonski-Perec traz experiência global para os planos de quimioterapia no Hadassah Medical Center.

• Professora de Oncologia na Universidade Hebraica
• Liderou o Instituto de Oncologia por mais de uma década
• Premiada com bolsa da Escola de Medicina Hadassah
• Membro de múltiplas sociedades internacionais de câncer